• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • LASIK
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

Poll results: How comfortable are you with including biosimilars in your treatment plans?

Poll

See the results from our recent poll!

Optometry Times asked our audience, "How comfortable are you with including biosimilars in your treatment plans?" and the results are in!

The poll appeared on OptometryTimes.com and was promoted across social channels from Feb. 15 to Feb. 22, 2023.

10 ODs responded:

- 4 said, "Very excited to begin embracing biosimilars"

- 4 said, "Feeling comfortable exploring biosimilar options, though cautiously"

- 0 said, "Still hesitant, I need to learn more about biosimilars"

- 2 said, "With the knowledge of biosimilars I have, I am not comfortable including this in my treatment plans"

To learn more about biosimilars for AMD, check out Euin Cheong, OD's piece on "Introduction to biosimilars for AMD."

Related Videos
Edmund Tsui, MD, details what insights swept-source anterior segment OCT images may give to determining eye inflammation
Michael Chaglasian, OD, details success of new OCT device at the ARVO 2024 meeting
Emily Chew, MD, outlines her lecture that landed her the Proctor Award at ARVO 2024
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Kelsey Roelofs, MD, details the best methods to identify thyroid eye disease at CIME 2024
David A. Berntsen, OD, PhD, FAAO, outlines his presentation on the BLINK 2 study presented at the 2024 ARVO meeting
© 2024 MJH Life Sciences

All rights reserved.